Cargando…
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer comprises approximately 15%–20% of all breast cancers and is associated with a poor prognosis. The introduction of anti-HER2 therapy has significantly improved clinical outcomes for patients with HER2+ breast cancer, and multipl...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187060/ https://www.ncbi.nlm.nih.gov/pubmed/28236776 http://dx.doi.org/10.1016/j.breast.2017.01.010 |